Sign In
Buy FDMT
$10.18
+0.110 (+1.09%)
At Close: Jul 31, 2026
10 Stock Picks to Celebrate 45 Years of Schaeffer's
03:22pm, Wednesday, 29'th Jul 2026
Subscribers to Chart of the Week received this commentary on Sunday, July 26.
4D Molecular: 'Buy' Wet-AMD Study Readouts 2027 And DME Expansion Opportunity
02:16pm, Monday, 20'th Jul 2026
4D Molecular Therapeutics, Inc. maintains a Buy rating, driven by advancing 4D-150 gene therapy for Wet-AMD and DME into late-stage pivotal trials. FDMT's 4D-150 demonstrated up to 89% reduction in in
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
03:15pm, Saturday, 18'th Jul 2026
EMERYVILLE, Calif., July 18, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t
4DMT Announces New Employment Inducement Grants
04:05pm, Friday, 17'th Jul 2026
EMERYVILLE, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
04:05pm, Tuesday, 30'th Jun 2026
EMERYVILLE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
08:00am, Monday, 29'th Jun 2026
EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
08:00am, Monday, 29'th Jun 2026
EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t
Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?
10:45am, Tuesday, 23'rd Jun 2026
4D Molecular Therapeutics (FDMT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in
4DMT Announces New Employment Inducement Grants
04:05pm, Friday, 12'th Jun 2026
EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t
4D Molecular Therapeutics, Inc. (FDMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
12:22am, Wednesday, 10'th Jun 2026
4D Molecular Therapeutics, Inc. (FDMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies Global Healthcare Conference 2026 Transcript
05:52pm, Friday, 05'th Jun 2026
4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies Global Healthcare Conference 2026 Transcript
4DMT to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 27'th May 2026
EMERYVILLE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted th
4D Molecular Therapeutics, Inc. (FDMT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
06:30pm, Friday, 22'nd May 2026
4D Molecular Therapeutics, Inc. (FDMT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy
08:03pm, Saturday, 16'th May 2026
4D Molecular Therapeutics NASDAQ: FDMT executives said the company is seeing strong clinical trial momentum for its lead retinal gene therapy candidate, 4D-150, as it advances through late-stage devel
4DMT Announces New Employment Inducement Grants
04:05pm, Friday, 15'th May 2026
EMERYVILLE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted th
